logo

Halozyme Therapeutics, Inc. (HALO)



Trade HALO now with
  Date
  Headline
2/24/2021 10:48:52 PM Halozyme Therapeutics Announces Pricing Of Private Offering Of $700 Mln Of Convertible Senior Notes Due 2027
2/6/2021 5:19:00 AM Halo Agrees To Acquire Two Additional Los Angeles Dispensary License Applicants
1/11/2021 8:20:19 AM Halozyme Expects 2021 EPS Of $1.40 To $1.55, Represents 55%-70% Growth Over Expected 2020 EPS
12/23/2020 1:32:08 AM Halozyme Announces Roche Gets EU Approval For Phesgo Utilizing Halozyme's ENHANZE® Technology
12/18/2020 4:48:17 PM Halo Closes Acquisition Of Winberry Farms
11/23/2020 8:11:14 AM Horizon Therapeutics Plc And Halozyme Enter Global Collaboration And License Deal For ENHANZE Technology
11/23/2020 8:06:34 AM Halozyme Lifts 2020 Outlook
11/12/2020 8:29:57 AM Halozyme: FDA And EMA Seeking Approval Of Daratumumab SC Formulation, Known As DARZALEX FASPRO In The U.S.
11/5/2020 7:41:49 PM MGIC Investment & Halozyme Therapeutics Set To Join S&P MidCap 400
10/6/2020 2:16:37 AM Halozyme Announces Expansion Of Collaboration And License Deal With Argenx For ENHANZE Technology
9/17/2020 8:12:11 AM Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab
9/10/2020 8:04:22 AM Halozyme Unveils Janssen Submission For FDA Approval Of DARZALEX FASPRO For Light Chain Amyloidosis
6/29/2020 12:56:13 PM Roche Gets FDA Approval For Phesgo For Treatment Of HER2-Positive Breast Cancer
6/22/2020 8:09:07 AM Halozyme To Get $10 Mln Milestone Payment From Janssen On Commercial Sale In EU Subcutaneous Formulation Of DARZALEX
6/13/2020 8:54:15 AM Halozyme Therapeutics: Janssen Presents Data From Phase III ANDROMEDA Study
4/26/2020 9:43:44 PM Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme' ENHANZE For Multiple Myeloma
4/3/2020 11:32:34 PM Halo Announces Proposed Acquisition Of Nasalbinoid Natural Devices For C$5.1 Mln